[18]; stimuli were used at the following concentrations: CpG ODN 2006 PTO/PO (5′-tcgtcgttttgtcgttttgtcgtt-3′) 1 μm (MWG Biotech, Ebersberg, Germany); UV-irradiated BHK-CD40L and BHK-pTCF (1 : 10); recombinant human (rh) IL-4 (Miltenyi Biotec) 100 U/ml; goat anti-human IgM + IgG + IgA F(ab′)2 fragments (Jackson Immunoresearch, Westgrove, PA) 5 μg/ml;

SU6656 (Merck, Darmstadt, Germany) and R406[19] (Rigel Pharmaceuticals, San Franscisco, CA) (in DMSO). One hundred micrograms streptavidin-coated polystyrene beads (Bangs Laboratories, Fishers, IN; 0·13 μm or dragon-green 0·39 μm) were coupled with biotinylated anti-human IgM + IgA + IgG F(ab′)2 or 5′ biotinylated, non-PTO ODN (MWG Biotech), i.e. CpG 2006, GpC 2006 and poly-(T)20 (30 min), washed, resuspended in PBS and diluted 1 : 20 for stimulation. B-cell proliferation was assessed after 72 hr with an 8-hr [3H]thymidine pulse (1 μCi/well; Perkin Elmer, Hamburg, Germany). For bromodeoxyuridine (BrdU) assays B cells were BMS-777607 nmr stimulated in the presence of 0·5 μm BrdU (Roche, Mannheim, Germany) (4 days) and stained according to the protocol from BD Biosciences. Cells were stained following standard procedures.

For intracellular staining, cells were fixed with PBS/4% paraformaldehyde this website and stained in Fix & Perm Medium B (Invitrogen). Measurements were performed on a FACSCanto (BD Biosciences, Heidelberg, Germany). Antibodies were purchased from BD Biosciences: anti-human Igλ-PE (murine IgG1), Igκ-FITC (murine IgG1), IgD-FITC, heptaminol IgM-PE, CD5-allophycocyanin, CD5-FITC, CD20-Peridinin chlorophyll protein, CD19-PE, CD27-PE, murine IgG1-PE;

Santa Cruz: rabbit anti-human RAG-1 [sc-363 (K-20)], goat anti-human RAG-2 [sc-7623 (C-19)], goat anti-rabbit IgG-FITC, donkey anti-goat IgG-FITC; Novus Biologicals, Littleton, CO: mouse anti-human Ku70 mAb; DakoCytomation, Glostrup, Denmark: mouse IgG1; Sigma, Munich, Germany: rabbit anti-mouse IgG-FITC. The mean fluorescence intensity is given as ΔMFI = MFI(primary antibody) − MFI(secondary antibody or isotype control) to account for the differences in antibody binding due to the activation state of the cell. Cells were fixed with PBS/4% paraformaldehyde, blocked in PBS/0·1% saponin/5% FCS/2% non-fat dry milk and stained with anti-RAG-1 1 : 50, anti-RAG-2 1 : 50, anti-Ku70 1 : 50, mouse IgG1 1 : 50; goat anti-rabbit IgG-TexasRed 1 : 1000, donkey anti-goat IgG-TexasRed 1 : 1000 (Jackson Immunoresearch), anti-mouse IgG-FITC 1 : 400 and 0·1 μm DAPI (Invitrogen). Specificity of anti-RAG-1 was controlled using the immunization peptide (see Supplementary material, Fig. S1A). B cells incubated with dragon-green microsphere conjugates (3 hr) were stained with Hoechst dye. HEp2G cells were fixed, permeabilized, incubated with B-cell supernatants or intravenous immunoglobulin G (5 μg/ml, Octapharma, Langenfeld, Germany), washed, stained with biotinylated anti-human immunoglobulin, streptavidin-Dy647 (ImmunoTools, Friesoythe, Germany) and Hoechst dye.